Secretin-stimulated Amylase Release into Blood is Impaired in Type 1 Diabetes Mellitus

Swislocki, Arthur L; Noth, Robert H.; Hallstone, A; Kyger, Erich M.; Triadafilopoulos, George

doi:10.1055/s-2005-861478

Cited by 23 publications

(9 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patel et al [30] showed that insulin could stimulate amylase release from acinar cells in healthy and diabetic rats, but with a much-reduced effect in diabetic rats. Moreover, studies in patients with diabetes mellitus showed pancreatic exocrine tissue fibrosis and a reduced response to hormonal stimulation [31,32]. Our present study showed that the low serum amylase levels were associated with impaired insulin secretion and insulin action in type 2 diabetes.…”

Section: Discussionsupporting

confidence: 59%

Serum Amylase Levels in Relation to Islet β Cell Function in Patients with Early Type 2 Diabetes

Zhuang

Zhang

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

ObjectiveThe insulin-pancreatic acinar axis may play a major role in pancreatic function. Amylase is an exocrine enzyme that is produced by pancreatic acinar cells, and low serum amylase levels may be associated with endocrine diseases, such as metabolic syndrome and diabetes. We hypothesized that low serum amylase levels may be associated with impaired islet β cell function in type 2 diabetes. Therefore, we investigated the relationship between the serum amylase levels and islet β cell function in patients with early type 2 diabetes.MethodsThe cross-sectional study recruited 2327 patients with a mean of 1.71±1.62 years since their diagnosis of type 2 diabetes, and all participants were treated with lifestyle intervention alone. Serum amylase levels, the 75-g oral glucose tolerance test (OGTT) and metabolic risk factors were examined in all participants. The insulin sensitivity index (Matsuda index, ISIMatsuda) and insulin secretion index (ratio of total area-under-the-insulin-curve to glucose-curve, AUCins/glu) were derived from the OGTT. Integrated islet β cell function was assessed by the Insulin Secretion-Sensitivity Index-2 (ISSI-2) (ISIMatsuda multiplied by AUCins/glu).ResultsSerum amylase levels in the normal range were significantly correlated with ISIMatsuda, AUCins/glu and ISSI-2 (r = 0.203, 0.246 and 0.413, respectively, p<0.001). The association of the serum amylase levels with ISSI-2 (adjusted r = 0.363, p<0.001) was closer than the association with ISIMatsuda (adjusted r = 0.191, p<0.001) and AUCins/glu (adjusted r = 0.174, p<0.001) after adjusting for the anthropometric indices, time since the diagnosis of diabetes, lipid profiles, uric acid levels, estimated glomerular filtration rate, HbA1c levels, smoking and drinking using the partial correlation test. After adjusting for these metabolic risk factors in the multivariate regression analysis with the amylase levels as the dependent variable, ISSI-2 was the major independent contributor to the serum amylase levels (β = 0.416, t = 21.72, p<0.001). Meanwhile, in a comparison of the groups with the highest and lowest quartiles of serum amylase levels, the mean difference in logISSI-2 was 0.902 (95% CI 0.823 to 0.982), and after adjusting for metabolic risk factors, the mean difference in logISSI-2 was 0.610 (0.537 to 0.683).ConclusionsSerum amylase levels in the normal range are positively associated with integrated islet β cell function in patients with early type 2 diabetes, as assessed by ISSI-2.

show abstract

Section: Discussionsupporting

confidence: 59%

Serum Amylase Levels in Relation to Islet β Cell Function in Patients with Early Type 2 Diabetes

Zhuang

Zhang

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…First, the blood insulin levels were not measured. However, previous studies have shown positive correlations between amylase secretion and circulating C-peptide or 24-hr urinary C-peptide excretion in diabetic patients, principally in type 1 diabetes [10-12], suggesting that low circulating amylase may reflect low insulin secretion. Nevertheless, obese people with MetS and type 2 diabetes tend to show hyperinsulinemia to compensate for insulin resistance.…”

Section: Discussionmentioning

confidence: 99%

Low serum amylase in association with metabolic syndrome and diabetes: A community-based study

Nakajima

Nemoto

Muneyuki

et al. 2011

Cardiovasc Diabetol

View full text Add to dashboard Cite

BackgroundLow serum amylase levels may reflect impaired exocrine-endocrine relationship in the pancreas. However, few clinical studies have addressed this issue. Therefore, in this epidemiological study, we investigated whether low serum amylase was associated with the pathogenesis of impaired insulin action: metabolic syndrome (MetS) and diabetes.Research Design and MethodsSerum amylase, cardiometabolic risk factors, MetS (Adult Treatment Panel III criteria), and diabetes were examined in 2,425 asymptomatic subjects aged 30-80 years who underwent medical checkups recently (April 2009-March 2010) and 5 years ago.ResultsClinical variables, except for age and estimated glomerular filtration rate (eGFR), shifted favorably with increasing serum amylase levels. Plasma glucose levels at 1- and 2-hr during OGTT increased significantly with decreasing serum amylase levels. Multiple logistic analyses showed that, compared with highest quartile of serum amylase, lowest quartile was associated with increased risk for MetS and diabetes after adjustment for confounding factors [odds ratio (95% CI), 2.07 (1.39-3.07) and 2.76 (1.49-5.11), respectively]. In subjects who underwent checkups 5 years ago (n = 571), lower amylase at the previous checkup were associated with larger numbers of metabolic abnormalities at the recent checkup. The fluctuation over time in serum amylase levels in subjects with low serum amylase at the previous checkup was slight and was unaffected by kidney dysfunction.ConclusionsOur results indicate that low serum amylase is associated with increased risk of metabolic abnormalities, MetS and diabetes. These results suggest a pancreatic exocrine-endocrine relationship in certain clinical conditions.

show abstract

“…The level of increase in amylase was not dependent on the duration as this is reflected in the percentage relative changes observed between different days during the experiment. This result is contrary to the popularly reported low level concentration of serum amylase which have been empirically observed in clinical settings in patients with type 1 diabetes, type 2 diabetes with insulin dependence, or advanced overt pancreatitis [27,28,29]. It is upheld that the action of insulin is critical for the production of pancreatic amylase [30,31] as such the common etiology in these conditions may be depleted secretion of insulin from the pancreas [32].…”

Section: Discussionmentioning

confidence: 74%

The Role of Serum Alpha-Amylase and Glycogen Synthase in the Anti-Diabetic Potential of Terminalia catappa Aqueous Leaf Extract in Diabetic Wistar Rats

Ben

Asuquo

Owu

2019

AJRIMPS

View full text Add to dashboard Cite

Background: The endocrinal abnormalities in diabetes mellitus as one of the numerous metabolic disorders is associated with derangement in exocrine functions of the pancreas and ultimately influences blood glucose regulation. Aim: The study was aimed at assessing the role of alpha-amylase and glycogen synthase in anti-diabetic potential of Terminalia catappa in diabetic rats. Materials and Methods: Thirty five (35) Wistar rats were assigned to 5 groups of 7 animals each. Group 1 served as the control administered distilled water at 5ml/kg bodyweight and group 2 was a non diabetic group given orally, 130/kg body weight of aqueous leaf extract of Terminalia catappa. Groups 3, 4 and 5 received a single dose of 150mg/kg body weight of alloxan solution intraperitoneally to induce diabetes and rats with blood glucose levels ≥200mg/dl after 72 hours were considered diabetic. This was followed by oral administration of 5ml/kg bodyweight of distilled water, 130mg/kg body weight of Terminalia catappa leaf extract orally and subcutaneous administration of insulin, 0.75U/kg body weight to groups 3 (diabetic), 4(diabetic + extract) and 5 (diabetic + insulin) respectively. Results: The results showed significant (P<.05) increase in serum level of alpha-amylase and glycogen synthase in both non-diabetic extract treated and diabetic groups when compared to control. But these enzymes significantly (P<.05) reduced in diabetic extract and insulin treated groups when compared to the diabetic group. Conclusion: Therefore the hypoglycaemic potential of Terminalia catappa leaf extract could be attributed to its ability to reduce alpha-amylase level while lowered glycogen synthase might be secondary to reduction in blood glucose.

show abstract

Secretin-stimulated Amylase Release into Blood is Impaired in Type 1 Diabetes Mellitus

Cited by 23 publications

References 26 publications

Serum Amylase Levels in Relation to Islet β Cell Function in Patients with Early Type 2 Diabetes

Serum Amylase Levels in Relation to Islet β Cell Function in Patients with Early Type 2 Diabetes

Low serum amylase in association with metabolic syndrome and diabetes: A community-based study

The Role of Serum Alpha-Amylase and Glycogen Synthase in the Anti-Diabetic Potential of Terminalia catappa Aqueous Leaf Extract in Diabetic Wistar Rats

Contact Info

Product

Resources

About